摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,3aR,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one | 239100-30-2

中文名称
——
中文别名
——
英文名称
(1R,3aR,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one
英文别名
(1R,3aR,4S,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one;(1R,3aR,7aR)-1-[(2R,5S)-5,6-bis[[tert-butyl(dimethyl)silyl]oxy]-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-one
(1R,3aR,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one化学式
CAS
239100-30-2
化学式
C30H60O3Si2
mdl
——
分子量
524.976
InChiKey
BJPLJYXKSZJCKB-SEZGZLGISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    9.38
  • 重原子数:
    35
  • 可旋转键数:
    11
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.97
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (1R,3aR,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one四(三苯基膦)钯 sodium hexamethyldisilazane三乙胺 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 2.0h, 生成 1α,2β,3β-tris(triethylsilyloxy)-24S,25-di(tert-butyldimethylsilyloxy)-9,10-secocholesta-5,7,10(19)-triene
    参考文献:
    名称:
    Synthesis of putative metabolites of 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71)
    摘要:
    1 alpha,25-Dihydroxy-2 beta-(3-hydroxypropoxy)vitamin D-3 (ED-71), an analog of active vitamin D-3, 1 alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] is under phase III clinical trials in Japan for the treatment of osteoporosis and bone fracture prevention. Since ED-71 has a substituent at the 2 beta-position of the A-ring, it is recognized that the metabolic pathway of ED-71 might be more complicated than 1,25(OH)(2)D-3 because of metabolism at the 2 beta-position substituent in addition to the inherent metabolism of the side chain. To clarify the metabolism of hydroxypropoxy substituent of the 2 beta-positon and a combination of metabolism between side chain and 2 beta-positon, four putative metabolites of ED-71 have been prepared as authentic samples. The metabolites at the 2 beta-positon, the methyl ester derivative considered as an ester standard of the oxidized metabolite and the tetraol derivative as the truncated metabolite were synthesized from alpha-epoxide, a key intermediate of ED-71 synthesis. The combination metabolites between side chain and 2 beta-positon, the 24(S)- and 24(R)-pentaols were synthesized using Trost's convergent method. (c) 2006 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.steroids.2005.11.001
  • 作为产物:
    描述:
    (S)-2-((3R,3aR,7S,7aR)-octahydro-7-hydroxy-3a-methyl-1H-inden-3-yl)propyl 4-methylbenzenesulfonate 在 咪唑2,6-二甲基吡啶盐酸 、 lithium aluminium tetrahydride 、 正丁基锂 、 4 A molecular sieve 、 N-甲基吗啉氧化物 、 sodium iodide 作用下, 以 四氢呋喃正己烷二氯甲烷N,N-二甲基甲酰胺丙酮 为溶剂, 反应 49.0h, 生成 (1R,3aR,7aR)-1-[(1R,4S)-4,5-di(tert-butyldimethylsilyloxy)-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-one
    参考文献:
    名称:
    Synthesis of putative metabolites of 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71)
    摘要:
    1 alpha,25-Dihydroxy-2 beta-(3-hydroxypropoxy)vitamin D-3 (ED-71), an analog of active vitamin D-3, 1 alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] is under phase III clinical trials in Japan for the treatment of osteoporosis and bone fracture prevention. Since ED-71 has a substituent at the 2 beta-position of the A-ring, it is recognized that the metabolic pathway of ED-71 might be more complicated than 1,25(OH)(2)D-3 because of metabolism at the 2 beta-position substituent in addition to the inherent metabolism of the side chain. To clarify the metabolism of hydroxypropoxy substituent of the 2 beta-positon and a combination of metabolism between side chain and 2 beta-positon, four putative metabolites of ED-71 have been prepared as authentic samples. The metabolites at the 2 beta-positon, the methyl ester derivative considered as an ester standard of the oxidized metabolite and the tetraol derivative as the truncated metabolite were synthesized from alpha-epoxide, a key intermediate of ED-71 synthesis. The combination metabolites between side chain and 2 beta-positon, the 24(S)- and 24(R)-pentaols were synthesized using Trost's convergent method. (c) 2006 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.steroids.2005.11.001
点击查看最新优质反应信息

文献信息

  • Synthesis and biological characterization of 1α,24,25-trihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (24-hydroxylated ED-71)
    作者:Susumi Hatakeyama、Akira Kawase、Yasushi Uchiyama、Junji Maeyama、Yoshiharu Iwabuchi、Noboru Kubodera
    DOI:10.1016/s0039-128x(00)00149-5
    日期:2001.3
    24-Hydroxylated derivatives were synthesized in 24(R) and 24(S) forms by the convergent method as analogs related to 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D(3). In the convergent synthesis, the A-ring fragment, synthesized from diethyl D-tartarate, and the C/D-ring fragments in 24(R) and 24(S) forms (vitamin D numbering), obtained from vitamin D(2) via the Inhoffen-Lythgoe diol, were
    通过会聚方法以24(R)和24(S)形式合成24-羟基衍生物,作为与1α,25-二羟基-2β-(3-羟基丙氧基)维生素D(3)相关的类似物。在收敛性合成中,由D-酒石酸二乙酯合成的A环片段和24(R)和24(S)形式的C / D环片段(维生素D编号)从维生素D(2)获得通过Inhoffen-Lythgoe二醇,以中等收率偶联,得到1alpha,24(R),25-三羟基-2beta-(3-羟基丙氧基)维生素D(3)和1alpha,24(S),25-三羟基-2beta -(3-羟基丙氧基)维生素D(3)。在初步的生物学评估中,与母体化合物相比,1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)维生素D(3)的24-羟基化导致对维生素D结合蛋白的体外亲和力减弱,体内钙化活性降低。
  • Synthesis of putative metabolites of 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71)
    作者:Yoshiyuki Ono、Hiroyoshi Watanabe、Ikuo Taira、Keisuke Takahashi、Jun Ishihara、Susumi Hatakeyama、Noboru Kubodera
    DOI:10.1016/j.steroids.2005.11.001
    日期:2006.7
    1 alpha,25-Dihydroxy-2 beta-(3-hydroxypropoxy)vitamin D-3 (ED-71), an analog of active vitamin D-3, 1 alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] is under phase III clinical trials in Japan for the treatment of osteoporosis and bone fracture prevention. Since ED-71 has a substituent at the 2 beta-position of the A-ring, it is recognized that the metabolic pathway of ED-71 might be more complicated than 1,25(OH)(2)D-3 because of metabolism at the 2 beta-position substituent in addition to the inherent metabolism of the side chain. To clarify the metabolism of hydroxypropoxy substituent of the 2 beta-positon and a combination of metabolism between side chain and 2 beta-positon, four putative metabolites of ED-71 have been prepared as authentic samples. The metabolites at the 2 beta-positon, the methyl ester derivative considered as an ester standard of the oxidized metabolite and the tetraol derivative as the truncated metabolite were synthesized from alpha-epoxide, a key intermediate of ED-71 synthesis. The combination metabolites between side chain and 2 beta-positon, the 24(S)- and 24(R)-pentaols were synthesized using Trost's convergent method. (c) 2006 Elsevier Inc. All rights reserved.
查看更多

同类化合物

(5β,6α,8α,10α,13α)-6-羟基-15-氧代黄-9(11),16-二烯-18-油酸 (3S,3aR,8aR)-3,8a-二羟基-5-异丙基-3,8-二甲基-2,3,3a,4,5,8a-六氢-1H-天青-6-酮 (2Z)-2-(羟甲基)丁-2-烯酸乙酯 (2S,4aR,6aR,7R,9S,10aS,10bR)-甲基9-(苯甲酰氧基)-2-(呋喃-3-基)-十二烷基-6a,10b-二甲基-4,10-dioxo-1H-苯并[f]异亚甲基-7-羧酸盐 (+)顺式,反式-脱落酸-d6 龙舌兰皂苷乙酯 龙脑香醇酮 龙脑烯醛 龙脑7-O-[Β-D-呋喃芹菜糖基-(1→6)]-Β-D-吡喃葡萄糖苷 龙牙楤木皂甙VII 龙吉甙元 齿孔醇 齐墩果醛 齐墩果酸苄酯 齐墩果酸甲酯 齐墩果酸乙酯 齐墩果酸3-O-alpha-L-吡喃鼠李糖基(1-3)-beta-D-吡喃木糖基(1-3)-alpha-L-吡喃鼠李糖基(1-2)-alpha-L-阿拉伯糖吡喃糖苷 齐墩果酸 beta-D-葡萄糖酯 齐墩果酸 beta-D-吡喃葡萄糖基酯 齐墩果酸 3-乙酸酯 齐墩果酸 3-O-beta-D-葡吡喃糖基 (1→2)-alpha-L-吡喃阿拉伯糖苷 齐墩果酸 齐墩果-12-烯-3b,6b-二醇 齐墩果-12-烯-3,24-二醇 齐墩果-12-烯-3,21,23-三醇,(3b,4b,21a)-(9CI) 齐墩果-12-烯-3,11-二酮 齐墩果-12-烯-2α,3β,28-三醇 齐墩果-12-烯-29-酸,3,22-二羟基-11-羰基-,g-内酯,(3b,20b,22b)- 齐墩果-12-烯-28-酸,3-[(6-脱氧-4-O-b-D-吡喃木糖基-a-L-吡喃鼠李糖基)氧代]-,(3b)-(9CI) 鼠特灵 鼠尾草酸醌 鼠尾草酸 鼠尾草酚酮 鼠尾草苦内脂 黑蚁素 黑蔓醇酯B 黑蔓醇酯A 黑蔓酮酯D 黑海常春藤皂苷A1 黑檀醇 黑果茜草萜 B 黑五味子酸 黏黴酮 黏帚霉酸 黄黄质 黄钟花醌 黄质醛 黄褐毛忍冬皂苷A 黄蝉花素 黄蝉花定